This week's roundup of Houston innovators includes Sarah Groen of Bell & Bly Travel, Alex Reed of Fluence Analytics, and Bettina Beech of UH. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from travel to analytics— recently making headlines in Houston innovation.

Sarah Groen, founder of Bell and Bly Travel

Sarah Groen, travel entrepreneur and longtime Houston tech ecosystem member, joins the Houston Innovators Podcast. Photo courtesy of Bell and Bly Travel

It's been a scary time for travel-related businesses, and Sarah Groen has had to get innovative to maintain her business as a travel adviser. Lucky for Groen, who has a long career in tech and innovation, she had all the right pivots, including offering digital travel packages, launching a new podcast, and more.

"During COVID, a lot of businesses either shutdown or took a pause, but we accelerated," Groen says.

Groen her career on the Houston Innovators Podcast. She also gives some strategic advice for founders — like trusting your gut and reading the signs when it comes to product-market fit — on the podcast. Click here to read more and stream the episode.

Alex Reed, co-founder and CEO of Fluence Analytics

Alex Reed joined InnovationMap for a Q&A on the company's move to Houston and its growth plans. Photo courtesy of Fluence Analytics

Alex Reed watched his father work in the labs on his research as he grew up, but he realized his future wasn't in the lab. Instead, he launched a career in taking that research and turning it into a company.

Founded in 2012 in New Orleans, Fluence Analytics has entered its next phase of growth by moving its headquarters to Houston following a $7.5 million venture capital raise.

We're working with the Houston of today, but also the Houston of tomorrow," Reed tells InnovationMap in a Q&A. Click here to read more.

Bettina Beech, chief population health officer at the University of Houston

Bettina Beech is a newly named AIM-AHEAD coordinating center team member. Photo via UH.edu

The University of Houston has joined in on a national initiative to increase the diversity of artificial intelligence researchers, according to a news release from the school. Unfortunately, AI — designed by humans — mimics human decision making through its choice of algorithms. This means that the same biases humans deal with have made it into the AI decision making too. These gaps can lead to continued disparities and inequities for underrepresented communities especially in regards to health care, job hiring, and more.

"Beyond health care, AI has been used in areas from facial recognition to self-driving cars and beyond, but there is an extreme lack of diversity among the developers of AI/ML tools. Many studies have shown that flawed AI systems and algorithms perpetuate gender and racial biases and have resulted in untoward outcomes," says Bettina Beech, chief population health officer at the University of Houston and newly named AIM-AHEAD coordinating center team member.

The initiative will bring together collaborators and experts across AI and machine learning, health equity research, data science training, data infrastructure and more. The other universities involved include: University of Colorado-Anschutz Medical Center in Aurora; University of California, Los Angeles; Meharry Medical College in Nashville; Morehouse School of Medicine in Atlanta; Johns Hopkins University, and Vanderbilt University Medical Center. Click here to read more.

Sarah Groen, travel entrepreneur and longtime Houston tech ecosystem member, joins the Houston Innovators Podcast. Photo courtesy of Bell and Bly Travel

Innovative travel adviser talks Houston tech and advice for female founders

houston innovators podcast episode 104

When the pandemic hit, it's safe to say that everyone in the travel industry panicked. Sarah Groen, who founded her company Bell and Bly Travel in 2017, caters her expertise to planning luxury travel experiences, and she didn't want her clients to forget about her expertise as the uncertainty of the pandemic continued. So, she got creative.

"Every single client who had a trip canceled, we sent them a digital package to help them feel like they were traveling," Groen says on this week's episode of the Houston Innovators Podcast. For example, if a client's trip to Italy canceled, Groen and her staff provided links to recipes of Italian dishes, virtual museum tours, and more.

"We didn't make money on that," Groen says. "We spent money to be able to have the bandwidth to be able to do that for our clients."

It's during this time thar Groen also launched her podcast, Luxury Travel Insider, where she gathers experts to discuss destinations.

It's these innovative endeavors that put Groen and Bell and Bly Travel on the map for Virtuoso's award — which Groen describes as the Oscars of the travel industry. She took home the title of "most innovative travel advisor" at the 2021 awards.

"During COVID, a lot of businesses either shutdown or took a pause, but we accelerated," Groen says.

The award is incredibly special to Groen she says especially to her background in tech. A native Houstonian, Groen went to the West Coast for her education. Despite loving her hometown, she says she returned kicking and screaming because she wanted to do something entrepreneurial, and Houston didn't yet have much to speak of in terms of a startup ecosystem.

So, like any good entrepreneur who sees a need in the market, she did it herself and co-founded Surge, an energy-focused accelerator. But it was a struggle to get momentum.

"But at that time, we couldn't even get the mayor to pay attention to us. We had people applying to our program and moving their companies from other cities and countries in some cases," Groen says. "But I think Surge starting was a big turning point."

Surge — which was co-founded by Kirk Coburn, who now is the investment director for Shell Ventures — officially shut down in 2016.

But things have changed within the Houston innovation ecosystem, and Groen discusses the transformation as she's observed it on the show. She also gives some strategic advice for founders — like trusting your gut and reading the signs when it comes to product-market fit — on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.